Complex Made Simple

Astellas Pharma Middle East launches XTANDI in Lebanon

XTANDI™ improves survival rate for patients with metastatic castration-resistant prostate cancer1.

Astellas Pharma Middle East, North and Sub-Saharan Africa (MENA/SSA), recently launched XTANDI (enzalutamide) in Lebanon.

Enzalutamide is indicated for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.

The newly launched enzalutamide, an androgen receptor signalling inhibitor, has shown to increase the survival rate of men suffering from mCRPC.

Prof. Fadi Farhat, President of Lebanese Oncology Society and Head of Hematology & Oncology at Hammoud Hospital UMC, Beirut, said: “The scientific community’s battle with cancer is ongoing. Prostate cancer is among the most common diseases threatening men of older age groups. As a consequence of late diagnosis, it is often the case that men who suffer from the disease are incurable. Relapse following conventional treatment is also problematic.”

“Treatment of prostate cancer depends on factors including malignancy and expansion of the disease. Hormone therapy is considered fundamental in the treatment of advanced and extensive prostate cancer. This treatment deprives the disease of the male hormone that feeds it, so the tumor shrinks and diminishes. In most cases the response to traditional hormone therapy is temporary and lasts for about two years, after which hormone therapy alone becomes insufficient for controlling the disease. Palliative therapy is generally used to treat extensive cancer that is non-responsive to traditional hormone therapy, offering the patient extended survival and reduced pain”, commented Prof. Muhammed Bulbul, Clinical Professor of Surgery at the American University of Beirut Medical Center.